vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a research report on Monday, December 9th. They issued a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Stock Performance

VTVT stock opened at $21.70 on Friday. vTv Therapeutics has a fifty-two week low of $8.10 and a fifty-two week high of $30.99. The business’s 50 day moving average price is $15.31 and its two-hundred day moving average price is $14.93. The company has a market capitalization of $69.22 million, a price-to-earnings ratio of -4.79 and a beta of 0.73.

Institutional Trading of vTv Therapeutics

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics in the 4th quarter worth approximately $25,000. Geode Capital Management LLC lifted its position in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares in the last quarter. Finally, FMR LLC bought a new position in vTv Therapeutics in the 3rd quarter valued at approximately $2,402,000. 17.51% of the stock is owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.